past
two
decad
sever
nucleic
acidsbas
therapeut
approach
investig
treatment
duchenn
muscular
dystrophi
dmd
exon
skip
via
splice
switch
oligonucleotid
sso
bypass
mutat
exon
dystrophin
gene
shown
great
promis
approach
sso
target
splice
site
dystrophin
premrna
induc
exon
skip
enabl
restor
open
read
frame
give
rise
express
truncat
function
dystrophin
protein
earli
studi
establish
viabil
strategi
anim
model
mostli
mdx
mice
dmd
recent
smallscal
clinic
trial
use
methyl
phosphorothio
phosphorodiamid
morpholino
oligom
pmo
also
establish
proofofconcept
applic
exon
skip
potenti
treatment
dmd
howev
system
administr
nake
sso
poorli
activ
induc
dystrophin
restor
skelet
muscl
almost
complet
inact
even
except
high
dose
import
dmdaffect
tissu
heart
clinic
translat
exonskip
strategi
thu
requir
implement
effici
deliveri
strategi
nonvir
vector
base
short
peptid
call
cellpenetr
peptid
cpp
intens
investig
recent
year
context
dmd
advanc
made
sso
mostli
uncharg
pmo
bind
rna
high
affin
coval
link
cpp
give
rise
seri
conjug
term
peptidepmo
ppmo
initi
studi
conduct
argininerich
rxr
peptid
x
stand
aminohexano
acid
later
rxrrbr
bpeptid
deriv
allow
exon
skip
dystrophin
rescu
much
lower
dose
free
sso
skelet
muscl
bpeptid
also
exhibit
activ
heart
parallel
conjug
propos
modifi
improv
serum
stabil
biolog
activ
profil
give
rise
new
class
pmopna
intern
peptid
call
pip
develop
pip
peptid
led
introduct
central
hydrophob
core
motif
ilfqi
sequenc
gener
seri
ppmo
ppmo
extens
screen
mdx
mous
model
dmd
identifi
promis
candid
allow
highdystrophin
restor
skelet
cardiac
muscl
although
lower
effici
latter
one
addit
structureact
studi
use
start
sequenc
carri
identifi
element
peptid
import
improv
cardiac
deliveri
novel
deriv
name
peptid
data
show
heart
muscl
activ
due
presenc
central
acid
hydrophob
sequenc
exact
sequenc
seem
less
import
length
among
ppmo
belong
famili
chosen
studi
pharmacokinet
biodistribut
muscl
physiolog
howev
littl
known
date
concern
cellular
traffick
pmo
ppmo
differ
muscl
cell
type
high
dose
nake
pmo
allow
effici
deliveri
dmdaffect
skelet
muscl
vivo
unaid
cellular
uptak
pmo
thought
depend
increas
sarcolemm
membran
permeabl
lack
dystrophin
render
cellular
membran
prone
mechan
stressinduc
disrupt
make
leaki
howev
knowledg
direct
evid
support
hypothesi
also
unknown
major
differ
uptak
pmo
ppmo
undifferenti
differenti
skelet
muscl
cell
ie
myoblast
myotub
would
respons
often
uneven
restor
dystrophin
differ
muscl
fibr
furthermor
heart
muscl
alway
seem
repres
challeng
barrier
achiev
effici
dystrophin
correct
nake
pmo
weakli
activ
high
repeat
dose
tissu
wherea
ppmo
conjug
activ
give
less
activ
heart
skelet
muscl
studi
compar
exonskip
activ
cellular
traffick
relev
muscular
cell
name
mdx
cell
line
repres
skelet
muscl
primari
cardiomyocyt
isol
newborn
mdx
mice
well
wildtyp
skelet
cardiac
muscl
cell
acrxrrbrrxryqflirxrbrxrboh
b
x
amino
hexano
acid
synthes
standard
fmoc
chemistri
ctermin
carboxyl
acid
purifi
highperform
liquid
chromatographi
pmo
purchas
gene
tool
llc
corval
linker
label
conjug
pmo
amid
linkag
via
linker
describ
carri
label
unless
specif
mention
figur
unlabel
unlabel
synthes
previous
describ
murin
mdx
myoblast
cultur
gelatin
coat
flask
dulbecco
modifi
eagl
medium
dmem
paa
laboratori
supplement
heatinactiv
fetal
bovin
serum
fb
gold
paa
laboratori
chicken
embryo
extract
seralab
penicillinstreptomycinneomycin
antibiot
mixtur
psn
gibco
peprotech
murin
myoblast
atcc
grown
dmem
supplement
heat
inactiv
fb
paa
laboratori
psn
cell
seed
gelatin
coat
plate
densiti
cellml
left
day
use
undifferenti
myoblast
differenti
myotub
cell
grown
dmem
supplement
hors
serum
sigmaaldrich
psn
day
mdx
day
cell
differenti
mdx
cell
monitor
measur
troponin
level
western
blot
data
shown
primari
cardiomyocyt
isol
ventricl
newborn
wildtyp
j
mice
charl
river
mdx
mice
provid
wood
enzymat
digest
collagenas
serlabo
technolog
pancreatin
sigmaaldrich
describ
previous
briefli
freshli
isol
cell
seed
flask
allow
select
adhes
cardiac
fibroblast
plate
medium
ml
dmem
paa
laboratori
ml
sigmaaldrich
ml
glutamax
life
technolog
ml
ps
ml
hors
serum
hs
sigmaaldrich
ml
fb
paa
laboratori
cardiomyocyt
remain
supernat
seed
well
cultur
plate
coat
gelatin
sigmaaldrich
cardiomyocyt
use
day
beat
cellsml
mdx
myoblast
seed
gelatin
coat
plate
grown
day
myoblast
differenti
myotub
mention
earlier
text
cellsml
cardiomyocyt
seed
gelatin
coat
wellplat
grown
beat
observ
day
thereaft
cell
incub
unlabel
label
pmo
indic
concentr
transfect
carri
final
volum
plate
microscopi
h
optimem
complet
medium
posttreat
condit
complet
medium
ad
well
incub
label
pmo
cell
wash
twice
pb
lyse
glb
buffer
promega
lysat
transfer
black
nonbind
plate
greiner
fluoresc
measur
tecan
plate
reader
ex
nmem
nm
protein
concentr
measur
bca
kit
pierc
tecan
plate
reader
ab
nm
total
rna
extract
use
nucleospin
kit
machereynagel
singl
well
h
treatment
trizol
extract
tri
rna
isol
reagent
sigmaaldrich
pool
duplic
h
treatment
per
manufactur
instruct
total
rna
quantif
done
use
thermo
scientif
ng
rna
templat
use
rtpcr
reaction
use
geneamp
rna
pcr
kit
invitrogen
life
technolog
genespecif
primer
aat
tct
gcc
aat
tgc
ttc
agc
ttg
tgt
cat
cycl
condit
follow
first
step
min
min
min
second
step
min
follow
cycl
min
min
final
extens
min
two
microlit
rtpcr
product
use
templat
secondari
nest
pcr
use
amplitaq
gold
dna
polymeras
kit
invitrogen
life
technolog
genespecif
primer
agt
cta
cca
ccc
tat
cag
gcc
ttt
aag
gct
tcc
cycl
condit
follow
min
follow
cycl
min
min
final
extens
min
product
fraction
electrophoresi
agaros
gel
v
h
quantifi
percentag
exon
skip
es
densitometr
analysi
biorad
es
calcul
densitometr
valu
band
relat
band
full
length
cellsml
seed
gelatin
coat
plate
grown
day
differenti
mention
earlier
text
cell
pretreat
min
inhibitor
provid
sigmaaldrich
mm
mm
ddg
atpdeplet
atp
chlorpromazin
cpz
clathrinmedi
endocytosi
inhibit
nystatin
ny
genistein
filipin
iii
caveolaemedi
endocytosi
inhibit
nethylnisopropyl
amilorid
eipa
macropinocytosi
inhibit
thereaft
cell
treat
h
presenc
inhibitor
wash
twice
pb
cell
lyse
glb
buffer
promega
cell
lysat
evalu
fluoresc
spectroscopi
rtpcr
describ
earlier
text
cellsdish
mdx
seed
gelatin
coat
dish
grown
day
myoblast
differenti
mention
earlier
text
cellsdish
cardiomyocyt
seed
gelatin
coat
dish
grown
cell
beat
day
cell
transfect
pmocf
h
h
ten
minut
end
incub
hoechst
dye
invitrogen
life
technolog
ad
dish
visual
nucleu
excess
conjug
dye
elimin
wash
pb
final
ml
optimem
ad
final
volum
trypan
blue
solut
invitrogen
life
technolog
ad
quench
extracellular
fluoresc
fluoresc
imag
captur
immedi
use
zeiss
axiovert
fluoresc
microscop
axio
vision
softwar
carl
zeiss
valu
express
multipl
comparison
group
assess
oneway
anova
post
hoc
test
test
appropri
p
valu
note
p
p
data
analyz
use
graphpad
prism
graphpad
softwar
san
diego
california
usa
first
aim
confirm
potenti
induc
exon
skip
wellestablish
skelet
muscl
model
dmd
ie
murin
mdx
cell
track
intracellular
compart
pmo
part
conjug
fluorescein
compound
use
throughout
experi
indic
otherwis
vitro
differenti
mdx
myotub
verifi
morpholog
express
troponin
marker
treat
increas
concentr
rang
nm
exon
skip
evalu
h
treatment
nest
rtpcr
line
previou
report
induc
high
level
exon
skip
dosedepend
manner
figur
reach
full
skip
nm
valu
ie
concentr
requir
achiev
exon
skip
nm
calcul
figur
transfect
carri
serumfre
medium
deliveri
potenti
cppbase
vector
often
neg
influenc
presenc
serum
protein
explor
impact
serum
protein
transfect
experi
carri
parallel
serumsuppl
transfect
medium
presenc
serum
impact
exonskip
activ
figur
even
slightli
lower
valu
nm
regist
figur
next
evalu
exonskip
activ
undifferenti
mdx
myoblast
found
much
lower
myotub
even
nm
unabl
induc
full
exon
skip
figur
nm
record
mdx
myoblast
data
shown
lower
mdx
myotub
also
monitor
skip
h
posttreat
pronounc
exonskip
activ
achiev
compar
h
treatment
h
nm
supplementari
figur
also
verifi
unlabel
conjug
similar
biolog
activ
profil
compar
fluoresc
label
conjug
supplementari
figur
taken
togeth
studi
show
enabl
effici
exon
skip
low
concentr
indic
valu
complet
resist
interfer
serum
protein
line
abil
restor
effici
dystrophin
express
system
administr
mdx
mice
dmdaffect
skelet
muscl
report
permeabl
healthi
muscl
increas
leaki
propos
possibl
explan
activ
nake
sso
anim
model
clinic
trial
review
use
vitro
differenti
cell
model
normal
skelet
muscl
cell
evalu
exonskip
effici
comparison
mdx
myotub
shown
supplementari
figur
exonskip
effici
measur
h
posttreat
slightli
lower
differenti
myotub
nm
use
serumcontain
transfect
media
compar
mdx
myotub
figur
c
main
goal
elucid
cellular
traffick
establish
optim
experiment
condit
allow
cellular
uptak
exon
activ
measur
within
sampl
h
posttreat
time
point
found
optim
gener
strong
fluoresc
signal
supplementari
figur
allow
exon
detect
differenti
mous
mdx
myotub
treat
increas
concentr
rang
nm
cellular
uptak
monitor
fluoresc
spectroscopi
fac
analysi
perform
myotub
enter
cell
dosedepend
manner
mdx
myotub
although
uptak
nake
pmo
could
detect
even
nm
figur
minim
differ
uptak
profil
mdx
figur
supplementari
figur
myotub
observ
although
fluoresc
level
slightli
elev
myotub
evalu
exon
within
sampl
nest
rtpcr
dosedepend
uptak
corrobor
well
exonskip
level
mdx
figur
supplementari
figur
signific
differ
exon
skip
found
mdx
myotub
h
posttreat
line
uptak
data
reach
effici
cell
cytosol
nucleu
consid
major
hurdl
cppmediat
deliveri
oligonucleotid
case
cpp
effici
taken
remain
segreg
endocyt
vesicl
intracellular
fate
cpp
cargo
known
vari
highli
differ
cell
line
physiolog
condit
studi
uptak
intracellular
distribut
undifferenti
myoblast
differenti
myotub
mdx
cell
line
myoblast
myotub
treat
condit
vari
concentr
uptak
measur
fluoresc
spectroscopi
effici
taken
mdx
myotub
mdx
myoblast
figur
line
exonskip
activ
figur
similar
trend
observ
normal
myoblast
myotub
supplementari
figur
time
nake
pmo
taken
detect
level
ident
condit
figur
supplementari
figur
data
indic
intern
clearli
differ
undifferenti
myoblast
differenti
myotub
howev
differ
cellular
traffick
exonskip
activ
due
higher
nuclei
densiti
myotub
use
fluoresc
microscopi
pictur
signific
differ
condit
found
nuclei
per
microscop
imag
myoblast
myotub
respect
n
data
shown
next
evalu
whether
differ
cellular
traffick
myoblast
myotub
mdx
cell
could
also
seen
mdx
myoblast
myotub
treat
cellular
distribut
analys
fluoresc
microscopi
strikingli
intracellular
distribut
rather
differ
mdx
myoblast
myotub
figur
myoblast
mostli
cytoplasm
punctat
distribut
pattern
reminisc
associ
endocyt
vesicl
littl
fluoresc
aros
cell
nuclei
longer
incub
period
h
h
well
h
posttreat
timelaps
experi
h
clearli
demonstr
dot
pattern
chang
time
data
shown
nearli
intern
pattern
observ
mdx
myotub
short
h
incub
figur
contrari
longer
incub
time
h
diffus
distribut
cytoplasm
myotub
strong
fluoresc
signal
record
nuclei
figur
similar
pattern
seen
myoblast
myotub
supplementari
figur
treatment
nake
pmo
yield
detect
fluoresc
signal
analys
condit
myoblast
myotub
mdx
cell
figur
supplementari
figur
result
indic
strong
differ
intracellular
traffick
differenti
undifferenti
skelet
muscl
cell
observ
increas
uptak
myotub
figur
importantli
stronger
nuclear
accumul
myotub
myoblast
cpp
gener
believ
use
differ
rout
endoytosi
gain
access
cell
especi
attach
cargo
molecul
determin
endocytot
pathway
involv
traffick
mdx
myotub
took
advantag
pharmacolog
inhibitor
major
endocyt
pathway
differenti
mdx
myotub
pretreat
inhibitor
ddg
atpdeplet
atp
chlorpromazin
cpz
clathrinmedi
endocytosi
inhibit
nystatin
ny
caveolaemedi
endocytosi
inhibit
nethylnisopropyl
amilorid
eipa
macropinocytosi
inhibit
cell
treat
nm
concentr
h
presenc
inhibitor
fluoresc
spectroscopi
analysi
show
energydeplet
significantli
decreas
uptak
figur
although
exonskip
activ
complet
abolish
figur
similar
effect
record
experi
carri
condit
energydepend
process
greatli
slow
data
shown
pharmacolog
inhibitor
endocytosi
nystatin
specif
caveolaemedi
endocytosi
pronounc
effect
uptak
figur
exon
effici
figur
involv
caveolaemedi
endocytosi
confirm
addit
caveola
inhibitor
filipin
iii
genistein
also
inhibit
uptak
exon
skipe
activ
supplementari
figur
cpz
eipa
inhibitor
clathrinmedi
endocytosi
macropinocytosi
respect
neglig
effect
cellular
deliveri
exonskip
activ
figur
similar
data
obtain
undifferenti
mdx
myoblast
figur
indic
observ
differ
intracellular
distribut
myoblast
myotub
could
aris
use
differ
uptak
pathway
unfortun
condit
plate
incub
volum
use
myotub
analysi
unabl
extract
enough
rna
repres
band
detect
myoblast
data
shown
altogeth
result
strongli
suggest
energydepend
process
involv
caveolaemedi
endocytosi
mainli
respons
uptak
mdx
cell
induc
biolog
activ
heart
muscl
remain
substanti
obstacl
ssobas
therapi
dmd
observ
nake
pmo
conjug
cpp
carrier
enabl
improv
dystrophin
rescu
cardiac
tissu
albeit
much
lower
level
compar
dystrophin
restor
skelet
muscl
stand
also
eventhough
far
activ
sso
deliveri
vector
heart
knowledg
investig
barrier
encount
heart
muscl
cell
might
imped
dystrophin
rescu
receiv
littl
attent
insight
studi
parallel
cellular
traffick
exonskip
activ
primari
cardiomyocyt
deriv
neonat
mdx
wildtyp
mice
heart
primari
mdx
wildtyp
cardiomyocyt
treat
h
intracellular
distribut
analys
fluoresc
microscopi
indic
punctuat
distribut
pattern
faint
nuclear
signal
remain
larg
segreg
endocyt
vesicl
fulli
differenti
cell
figur
right
panel
type
distribut
pattern
similar
one
seen
undifferenti
mdx
myoblast
also
confirm
limit
signal
cell
treat
pmo
figur
middl
panel
untreat
figur
left
panel
control
next
investig
exonskip
activ
mdx
wildtyp
cardiac
muscl
cell
normal
mdx
cardiomyocyt
treat
variou
concentr
rang
nm
exon
skip
evalu
h
posttreat
induc
dosedepend
exon
skip
normal
cardiomyocyt
rise
nm
mdx
cardiomyocyt
similar
effect
seen
exonskip
effici
rise
exon
skip
nm
nm
figur
thu
reach
significantli
lower
valu
skelet
muscl
cell
control
experi
nake
pmo
nm
concentr
fail
induc
exon
skip
cardiomyocyt
figur
c
varianc
mdx
myotub
exon
skip
increas
significantli
h
incub
cardiomyocyt
supplementari
figur
assess
whether
intern
pathway
cardiomyocyt
mdx
myotub
cellular
traffick
monitor
nm
concentr
fluoresc
spectrometri
presenc
variou
endocytosi
inhibitor
case
mdx
myotub
atp
deplet
neg
effect
uptak
figur
indic
involv
energydepend
mechan
interestingli
uptak
inhibit
cpz
figur
inhibitor
clathrinmedi
endocytosi
suggest
differ
pathway
use
cell
entri
cardiomyocyt
compar
skelet
muscl
cell
figur
collect
result
indic
also
cell
cultur
model
exon
skip
much
less
effici
heart
muscl
cell
skelet
muscl
cell
perfect
agreement
vivo
data
one
possibl
explan
could
taken
traffic
via
differ
endocyt
rout
two
differ
muscl
cell
type
coval
conjug
cpp
pmo
ppmo
shown
great
promis
preclin
model
dmd
particular
promot
effici
exon
skip
dystrophin
restor
skelet
muscl
importantli
activ
ppmo
cardiac
muscl
inject
intraven
mdx
mice
although
studi
progress
evalu
variou
vivo
paramet
littl
known
concern
cellular
intern
mechan
reason
lower
effici
cardiac
muscl
compar
muscl
type
therefor
compar
behaviour
skelet
heart
muscl
cellular
model
dmd
normal
phenotyp
exonskip
activ
skelet
mdx
myotub
remark
effici
low
concentr
reach
halfmaxim
effect
nm
figur
c
line
previou
data
much
effect
exon
skip
nake
pmo
previous
describ
ppmo
conjug
exampl
report
exonskip
level
rxr
bpmo
concentr
wherea
complet
exon
skip
achiev
concentr
nm
full
comparison
valu
difficult
sinc
complet
doserespons
curv
usual
report
one
major
drawback
frequent
associ
cppbase
vector
sensit
presenc
serum
effect
serum
often
document
contrari
exonskip
activ
even
slightli
increas
nm
presenc
serum
protein
figur
c
perhap
unexpect
pip
peptid
design
resist
degrad
proteasespeptidas
dmdaffect
muscl
report
leaki
due
increas
sarcolemma
membran
permeabl
aris
lack
dystrophin
leaki
also
thought
respons
improv
uptak
nake
sso
littl
direct
evid
provid
therefor
studi
behaviour
conjug
nake
pmo
differenti
myotub
dmd
ie
mdx
cell
normal
cell
phenotyp
result
indic
taken
type
myotub
compar
effici
accordingli
pariti
retain
exonskip
level
figur
moreov
uptak
intracellular
distribut
follow
similar
pattern
mdx
myotub
figur
supplementari
figur
slight
differ
biolog
activ
could
detect
howev
longer
incub
time
ie
h
exonskip
activ
mdx
myotub
nm
slightli
higher
myotub
nm
supplementari
figur
contrast
nake
pmo
taken
promot
signific
exon
skip
compar
concentr
collect
data
support
idea
cell
leaki
associ
lack
dystrophin
profound
effect
exonskip
effici
differenti
skelet
muscl
cell
promot
uptak
nake
pmo
least
cell
cultur
howev
conclus
care
drawn
cell
cultur
stress
physic
forc
occur
flex
muscl
report
dystrophin
restor
sso
differ
group
skelet
muscl
uniform
higher
activ
achiev
certain
muscl
tibiaii
anterior
context
hypothes
differ
ssopmo
uptak
depend
regen
capac
variou
muscl
type
ie
differ
activ
proport
myoblast
therefor
cellular
uptaketraffick
ssosppmo
undifferenti
differenti
cell
could
differ
data
show
intern
significantli
lower
myoblast
myotub
mdx
cell
supplementari
figur
moreov
intracellular
traffick
complet
differ
myoblast
mostli
confin
endocyt
vesicl
wherea
diffus
cytoplasm
distribut
strong
nuclear
accumul
preval
myotub
figur
supplementari
figur
howev
due
differ
densiti
nuclei
equal
amount
found
myoblast
myotub
data
shown
thu
seem
endosom
entrap
much
higher
myoblast
myotub
contribut
lower
exonskip
effici
myoblast
compar
myotub
nm
mdx
myoblast
versu
nm
myotub
slightli
lower
cellular
uptak
figur
regard
cardiac
muscl
system
inject
mdx
mice
remark
promot
dystrophin
express
heart
although
less
effici
skelet
muscl
reason
clear
recent
deriv
show
increas
nuclear
accumul
cardiac
muscl
tissu
live
heart
slice
compar
bpmo
worth
note
differ
invers
central
amino
acid
core
otherwis
show
ident
exonskip
level
mdx
skelet
muscl
cell
initi
report
use
shown
exon
skip
isol
mdx
mous
cardiomyocyt
appar
similar
mdx
cell
direct
comparison
pippmo
cardiac
muscl
cell
report
studi
primari
cardiomyocyt
deriv
neonat
mdx
wildtyp
mice
heart
cell
fulli
differenti
attest
beat
properti
show
less
effici
induc
exon
skip
cardiomyocyt
skelet
muscl
cell
cardiomyocyt
compar
nm
skelet
muscl
cell
figur
contrast
signific
differ
found
exonskip
activ
dmd
wildtyp
phenotyp
thu
skelet
cardiac
muscl
cell
dmd
phenotyp
seem
import
determin
effici
thoroughli
disprov
concept
pmo
ppmo
activ
mdx
cell
somehow
leaki
normal
cell
remain
entrap
endocyt
vesicl
pattern
reminisc
distribut
found
skelet
muscl
myoblast
therefor
unfavour
intracellular
traffick
greater
endosom
entrap
appear
major
caus
decreas
cardiac
activ
compar
skelet
muscl
cpp
conjug
variou
cargo
report
intern
cell
via
differ
endocyt
pathway
believ
import
intracellular
traffick
ultim
fate
insid
cell
earlier
studi
shown
hela
cell
line
wide
use
model
studi
sso
traffick
conjug
use
clathrinmedi
endocytosi
gain
access
cell
howev
studi
carri
cancer
cell
line
extrapol
muscl
cell
studi
aim
elucid
endocyt
pathway
would
respons
traffick
biolog
activ
muscl
cell
purpos
investig
impact
differ
pharmacolog
endoytosi
inhibitor
use
highest
nontox
concentr
given
cell
type
deliveri
differ
muscl
cell
type
focus
skelet
cardiac
muscl
cell
mdx
cell
traffick
energydepend
process
involv
caveolaemedi
endocytosi
figur
supplementari
figur
interestingli
trend
observ
undifferenti
myoblast
differenti
myotub
indic
lower
exonskip
activ
figur
myoblast
due
differ
uptak
pathway
figur
moreov
show
caveolaemedi
uptak
mechan
also
occur
cell
data
shown
confirm
endocytosi
rout
preferenti
one
skelet
muscl
cell
dmd
wildtyp
phenotyp
found
mdx
cell
traffick
energydepend
primari
cardiomyocyt
figur
intriguingli
contrast
skelet
muscl
cell
uptak
cardiomyocyt
occur
mainli
clathrinmedi
endocytosi
suggest
caveolaemedi
pathway
favour
promot
deliveri
nuclear
compart
could
provid
explan
higher
exonskip
activ
skelet
oppos
cardiac
muscl
conclus
comprehens
character
cellular
traffick
skelet
cardiac
muscl
model
dmd
first
nuclear
deliveri
effici
differenti
myotub
undifferenti
myoblast
skelet
muscl
cell
second
cardiomyocyt
behav
differ
mdx
myotub
term
uptak
pathway
term
cellular
traffick
case
segreg
within
endocyt
vesicl
seem
limit
nuclear
deliveri
consequ
exonskip
effici
cell
screen
primari
cardiomyocyt
isol
mdx
mice
addit
mdx
skelet
muscl
cell
vivo
evalu
would
predict
acceler
discoveri
new
effici
ppmo
lead
clinic
promis
develop
supplementari
data
avail
nar
onlin
associ
contr
le
myopathi
afm
mjg
mjaw
bl
work
laboratori
mjg
also
support
medic
research
council
mrc
laboratori
mjaw
medic
research
council
work
laboratori
bl
partli
fund
centr
nation
de
la
recherch
scientifiqu
cnr
eulifelong
learn
programm
erasmu
placement
support
sg
fund
open
access
charg
associ
contr
le
myopathi
afm
conflict
interest
statement
none
declar
